Sudden and irreversible diabetes triggered by immune checkpoint inhibitors will become more common as immunotherapy becomes the standard of care in cancer therapy, endocrinologists say. Fulminant islet autoimmunity that presents as diabetic ketoacidosis (DKA) has been considered a rare complication of anti-PD1 cancer therapies with an incidence of 0.4%. However, the ‘real world’ incidence may ...
Be vigilant for diabetes triggered by immune checkpoint inhibitors
By Michael Woodhead
20 Jun 2018